Limited adherence to growth hormone replacement in patients with traumatic brain injury
Kirstie C. Lithgow, Chantel Debert, Gregory A. Kline
Medicine, Cumming School of Medicine University of Calgary, T3B 5B8 CalgaryÂ Canada. E-mail: firstname.lastname@example.org
Background: Growth hormone deficiency is a recognized consequence of traumatic brain injury. The aim of this study was to determine adherence to human growth hormone therapy among patients with traumatic brain injury compared with patients with hypothalamic or pituitary disease.
Methods: A retrospective chart review of patients with traumatic brain injury referred for growth hormone stimulation testing since December 2013. Within the same electronic medical record, patients who were started on human growth hormone for aetiologies other than traumatic brain injury were reviewed. Adherence to therapy at 1-year follow-up was compared.
Results: Of the patients with traumatic brain injury, 12/23 (52%) returned for follow-up at 1 year to continue human growth hormone treatment, whereas 11/23 (48%) did not return at 1 year. Amongst the patients with non-traumatic brain injury: 25/29 (86%) continued human growth hormone treatment, vs 4/29 (14%) who did not return. A higher proportion of patients with non-traumatic brain injury continued human growth hormone treat-ment; Ï‡2 (1, nâ€‰=â€‰52)pâ€‰=â€‰7.238, pâ€‰=â€‰0.007.
Conclusion: There may be differences in the patient-perceived benefits of human growth hormone between these patient populations. However, it is important to consider the potential influences of cognitive and psychosocial dysfunction that can occur in patients with brain injuries.
Traumatic brain injuries can damage the pituitary gland and cause hormone deficiencies. Growth hormone deficiency is the most common hormone deficiency in patients with head injuries. These patients have adverse symptoms and poor quality of life, but it is not known whether these issues can be reversed or improved by growth hormone replacement therapy. This study investigated how many patients who started on growth hormone therapy after brain injury continued the treatment long-term. This allowed us to estimate whether the patients perceived such treatment to be beneficial. More than half (52%) of the patients with traumatic brain injury chose to continue growth hormone therapy for 1 year or longer. However, while some patients with brain injury may experience benefit from growth hormone replacement, it is possible that not all patients find growth hormone therapy helpful.
Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors.
You need to login/create an account to comment on articles. Click here to login/create an account